The biopharma industry has high ambitions to improve therapies for patients across many disease categories, drawing on a wealth of technological advances that have been emerging and maturing in recent years. Even after the mass mobilization against COVID-19, it is clear from the responses of the executives we surveyed that the sector has retained significant […]

As scientific and investment interests in vaccine development advances crescendo on the back of COVID-19, a Cincinnati-based biotech startup seeks to revolutionize the approach to influenza vaccinations.   In the shadows of a global, all-hands-on-deck and historic effort to develop, approve, manufacture, and distribute COVID-19 vaccines, Blue Water Vaccines has been quietly working on a separate […]

Scott Megaffin, CEO, Adastra Pharmaceuticals has taken on the challenge of developing first-in-class innovative therapeutics for the treatment of cancers with high unmet needs such as high-grade gliomas.  He talks about the Phase 1b clinical trial conducted by the National Cancer Institute evaluating zotiraciclib, a potent oral cyclin-dependent kinase 9 inhibitor in combination with temozolomide […]